Drugs / LAE005
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05390710 | Jun 2021 → Dec 2023 | triple-negative breast carcinoma | Laekna Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LAE005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05390710 ↗ |
| Route | Intravenous | “LAE005: 1200 mg IV Q3W” NCT05390710 ↗ |